Safety and Efficacy of Two Year Therapy with Spironolactone and Maximal RAAS Blockade: Effect on Urinary Proteinuria and Mean eGFR in African American Patients with Type II Diabetic Nephropathy
The NephroNet clinical trials consortium has designed and received IRB approval to conduct the MRA-ACE trial; a study in which African Americans with diabetic nephropathy are randomized to “standard of care” RAAS antihypertensive therapy alone or in combination with the aldosterone inhibitor Spironolactone. This study will determine whether combination therapy with Spironolactone and RAAS inhibitors has a specific protective effect on the progression of renal disease among African Americans.
While clinical data suggests that African Americans may specifically benefit from this combination therapy, no trial in African Americans to address this question has ever been conducted.
Click Here to access MRA-Ace Trial Dropbox Account